Isomorphic Labs, a Google-backed company spun out of DeepMind, has secured a massive $2.1 billion in Series B funding to accelerate its AI-driven drug discovery platform. The round was led by Thrive Capital and included major investors such as Alphabet, Abu Dhabi's MGX, Singapore's Temasek, and the UK's Sovereign AI fund. This capital will support the development of artificial intelligence tools designed to create new medicines, with the goal of bringing AI-designed drugs to patients within the next few years.
Meanwhile, Nvidia continues to dominate the AI hardware landscape, prompting UBS to reaffirm its buy rating with a $245 price target. Analysts point to strong spending on AI infrastructure as the primary driver, noting that Nvidia recently invested $420 million in Bittensor, a crypto AI protocol. This move underscores the growing connection between traditional AI hardware and decentralized blockchain networks.
In the cybersecurity sector, Exaforce raised $125 million to build AI agents called Exabots that automate security operations. These tools aim to reduce false alerts by up to 90 percent and allow security teams to investigate threats using natural language questions. The startup has already added 20 customers and expects to double that number by year-end.
Other developments include Everything.inc launching token trading on Kraken and expanding its AI tools, such as the interactive assistant Eva. Mashvisor introduced MashGPT to simplify real estate investment analysis, while BlackRock predicts the AI trade will expand beyond top stocks into semiconductors and data centers. C3.ai saw its stock drop 3.95 percent despite maintaining a market cap over $2 billion, and Zoomex warned that traditional liquidity metrics are failing in the new AI trading era.
Key Takeaways
['Isomorphic Labs raised $2.1 billion in Series B funding led by Thrive Capital and Alphabet.', 'The $2.1 billion investment will help Isomorphic Labs build AI tools to design new medicines.', 'Nvidia recently invested $420 million in Bittensor, a crypto AI protocol.', 'UBS maintains a buy rating on Nvidia with a $245 price target due to strong AI infrastructure spending.', 'Exaforce secured $125 million to develop AI agents that reduce false security alerts by 90 percent.', 'Everything.inc launched token trading on Kraken and rolled out new AI trading tools.', 'Mashvisor launched MashGPT to answer real estate investment questions in plain English.', 'BlackRock expects the AI trade to expand beyond the Magnificent 7 into semiconductors and data centers.', 'C3.ai stock fell 3.95 percent to $9.48 despite a market capitalization over $2 billion.', 'Zoomex warns that traditional liquidity metrics are ineffective in the current AI trading environment.']Isomorphic Labs Raises 2.1 Billion for AI Drug Design
Isomorphic Labs, a company spun out of DeepMind, raised 2.1 billion dollars in its second round of outside funding. The round was led by Thrive Capital and included investors like Alphabet, Abu Dhabi's MGX, Singapore's Temasek, and the UK's Sovereign AI fund. This money will help the company build artificial intelligence tools to design new medicines. The goal is to make AI-designed drugs a reality for patients.
Isomorphic Labs Secures 2.1 Billion for AI Drug Platform
Alphabet's biotech arm, Isomorphic Labs, raised 2.1 billion dollars in a series B funding round. Investors such as SoftBank Vision Fund 2, Fidelity, and Baillie Gifford led the investment. The funds will support the development of an AI-powered platform that uses machine learning to find new drug candidates. The company hopes to bring its first drug to market within the next few years.
Google-Backed Isomorphic Raises 2.1 Billion for Drug Discovery
Isomorphic Labs announced it raised 2.1 billion dollars to scale its AI-driven drug discovery platform. The round was led by Thrive Capital with participation from GV, Alphabet's venture arm, and the Bill and Melinda Gates Foundation. Founded in 2016 by researchers from the University of California, San Francisco, the company has already identified potential treatments for diseases like cancer and Alzheimer's. CEO Dr. Rahul Singh stated the funding will accelerate research and bring new medicines to patients faster.
Everything.inc Starts Token Trading on Kraken and Expands AI Tools
Everything.inc, formerly known as SmarDex, launched token trading on Kraken and other exchanges. The company is also rolling out new AI-powered products to help traders. Its AI trading assistant, Eva, is now interactive on X, allowing users to ask questions directly. Additionally, the Everything AI Terminal provides Bitcoin traders with signals based on order book activity instead of just price charts.
Everything.inc Begins Token Trading on Kraken with New AI Features
Everything.inc completed its pre-market funding and started trading its token on Kraken and other exchanges. The platform offers AI tools like Eva, an interactive trading assistant on X, and an AI Terminal for Bitcoin traders. The company uses a unified liquidity engine to support lending, borrowing, and trading from a single pool. Its goal is to make professional market insights accessible to regular traders.
C3.ai Stock Drops 3.95 Percent Despite Strong Fundamentals
C3.ai stock fell by 3.95 percent to settle at 9.48 dollars per share. The company has seen a 10 percent decline over the past week due to market volatility. However, the company remains strong with a market capitalization over 2 billion dollars and a pipeline of projects. CEO Thomas M. Siebel believes the company is well-positioned to meet growing demand for artificial intelligence and machine learning solutions.
Guide to Nominating Products for 2026 AI Innovation Awards
Businesses are moving from experimenting with AI to using it for real business impact. The Most Innovative AI Product Awards 2026 recognize organizations creating solutions for sectors like healthcare, FinTech, cybersecurity, and retail. These awards provide expert evaluation and global recognition for technologies that solve real-world challenges.
Mashvisor Launches MashGPT for Real Estate Investment Analysis
Mashvisor launched MashGPT, an AI tool that answers questions about U.S. rental investments in plain English. The platform lets users query data on cap rates, rental comparisons, and cash flow without using spreadsheets. It draws on a database of over 2 million properties across 95 percent of the country. Early users report cutting research time by 80 percent with this new conversational analyst.
UBS Keeps Buy Rating on Nvidia with 245 Dollar Target
UBS reaffirmed its buy rating on Nvidia with a price target of 245 dollars. Analyst Timothy Arcuri cited strong spending on AI infrastructure as the main reason for the call. Nvidia recently invested 420 million dollars in Bittensor, a crypto AI protocol, showing its commitment to the sector. This investment highlights the growing link between traditional AI hardware and decentralized blockchain networks.
Exaforce Raises 125 Million to Stop Cyberattacks with AI
Exaforce raised 125 million dollars in a series B round to build AI tools for cybersecurity. The company uses AI agents called Exabots to automate security operations and reduce false alerts by up to 90 percent. It recently introduced a feature called vibe hunting, which lets security teams investigate threats using natural language questions. The startup has added 20 customers and expects to reach 40 to 50 by the end of the year.
Zoomex Says Traditional Liquidity Metrics Fail in AI Trading Era
Zoomex issued a warning that traditional methods for measuring liquidity are no longer effective. The company notes that the rise of AI trading has changed how markets operate. As a result, old metrics may not accurately reflect the current state of market liquidity.
BlackRock Says AI Trade Will Expand Beyond Top Stocks
BlackRock's Jay Jacobs stated that the AI trade will grow beyond the Magnificent 7 stocks. Investors are increasingly looking at related industries like semiconductors, data centers, and power infrastructure. This shift reflects a move away from traditional stock-and-bond portfolios toward more diversified strategies.
Sources
- DeepMind Spinout Isomorphic Labs Raises $2.1 Billion to Design Drugs With AI
- Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model
- Google-backed Isomorphic raises $2.1 billion to scale AI-driven drug discovery
- Everything.inc launches token trading on Kraken, expands AI products
- Everything.inc launches token trading on Kraken, expands AI products
- C3.ai, Inc. (AI) Stock Falls Amid Market Uptick: What Investors Need to Know
- A complete guide to nominating for the Most Innovative AI Product Awards 2026
- Mashvisor Launches MashGPT: A Conversational AI Analyst for U.S. Rental Investment
- UBS reiterates buy rating on Nvidia with $245 price target, citing AI demand
- Exaforce raises $125M Series B to build AI for catching and stopping cyberattacks as they happen
- Zoomex Warns Traditional Liquidity Metrics Are Failing in the Age of AI Trading
- AI trade will continue to expand far beyond 'Magnificent 7' stocks: BlackRock
Comments
Please log in to post a comment.